Altered Biodistribution of Somatostatin Analogues After First Cycle of Peptide Receptor Radionuclide Therapy-Reference-Cited by-同舟云学术

Altered Biodistribution of Somatostatin Analogues After First Cycle of Peptide Receptor Radionuclide Therapy

Published:2011-07-01 Issue:19 Volume:29 Page:e579-e581
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Van Binnebeek Sofie¹,Deroose Christophe M.¹,Baete Kristof¹,Terwinghe Christelle¹,Vanbilloen Bert¹,Koole Michel¹,Haustermans Karin¹,Mortelmans Luc¹,Verslype Chris¹,Van Cutsem Eric¹,Verbruggen Alfons²,Mottaghy Felix M.³

Affiliation:

1. University Hospital Leuven, Leuven, Belgium

2. Catholic University Leuven, Leuven, Belgium

3. Universitätsklinikum Aachen, Aachen, Germany

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2010.34.3384

Reference11 articles.

1. Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings

2. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early Whole-Body Diffusion-weighted MRI Helps Predict Long-term Outcome Following Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumors;Radiology: Imaging Cancer;2022-05-01

2. Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs;Theranostics;2022

3. Altered Biodistribution of 68Ga-DOTATOC;Clinical Nuclear Medicine;2020-11-24

4. Inflammation-Based Index and 68Ga-DOTATOC PET–Derived Uptake and Volumetric Parameters Predict Outcome in Neuroendocrine Tumor Patients Treated with 90Y-DOTATOC;Journal of Nuclear Medicine;2019-12-05

5. Summary of emerging personalized medicine in neuroendocrine tumors: are we on track?;Journal of Gastrointestinal Oncology;2016-10